The Fibrin Pad CV Phase III Study

Inclusion Criteria: * Subjects ≥18 years of age, requiring an elective or urgent, open aortic surgical procedure utilizing cardiopulmonary bypass. Subjects in Japan between ≥18 and \<20 years of age will require consent by the subject's legal representative * Subjects must be willing to participate in the study and provide written informed consent. * Presence of an appropriate Target Bleeding Site (TBS) along the anastomotic suture line, involving a synthetic aortic graft, as identified intra-operatively by the investigator; Exclusion Criteria: * Subjects with known intolerance to blood products or to one of the components of the study product or unwilling to receive blood products; * Exposure to another investigational drug or device in a clinical trial within 30 days prior to surgery or anticipated in the 60 day follow up period after surgery. * Female subjects who are pregnant or nursing. * TBS is from a large defects in visible arteries or veins where the injured vascular wall requires repair and maintenance of vessel patency or where there would be persistent exposure of EVARREST™ Fibrin Sealant Patch to blood flow and/or pressure during absorption of the product; * TBS with major arterial bleeding requiring suture or mechanical ligation; * TBS involves an expanded polytetrafluoroethylene (ePTFE) graft * TBS within an actively infected field; * Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine; * Subjects with any intra-operative findings identified by the investigator that may preclude conduct of the study procedure;